Articles

August 18, 2011 — The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated with 26 percent relative risk reduction in cardiovascular death, myocardial...

August 3, 2011 — Texas Children's Hospital (TCH) is the nation's first pediatric hospital to both surgically implant and later explant a mechanical ventricular assist device (VAD) inside the chest...

July 21, 2011 – The U.S. Food and Drug Administration (FDA) today approved AstraZeneca’s blood-thinning drug ticagrelor (Brilinta) to reduce cardiovascular death and heart attack in patients with...

In a closely watched move viewed as a big step toward a paradigm shift in how heart valves are repaired in the United States, a U.S. Food and Drug Administration (FDA) advisory panel voted late...

Coronary revascularization does not always lead to coronary reperfusion. When readily available, percutaneous coronary intervention (PCI) using primary balloon angioplasty, with or without use of...

Swedish SCAAR Registry data were presented in May during the EuroPCR meeting in Paris. The 30-day ST-elevated myocardial infarction (STEMI) mortality was 4.4% in the femoral access group vs. 3.2%...

A review of recent transradial study data.

Transradial catheterization is increasingly becoming the access site of choice for many hospitals throughout the United States. Completing the procedure through the arm offers greater satisfaction...

A drug-eluting, self-expanding stent that does not use a drug-carrier polymer is before the U.S. Food and Drug Administration (FDA) final pre-market approval (PMA) review and a decision is...

Navigating through the world of coronary stents is about to become more complex.  A plethora of new products are on the horizon, which will utilize new platforms and alloys and present novel...